151751-Najiba-Chargi

263 Systemic therapy: the prospective PLATISMA study Table 1. Demographic and anthropometric measurements according to SMM status and DLT status Total N=45 N (%) or Mean, SD Without low SMM* n= 24 (53.3) Mean, SD With Low SMM n=21 (46.7) Mean, SD p Without DLT n= 19 (42.2) Mean, SD With DLT n= 26 (57.8) Mean, SD p Gender <0.01 0.7 Male 32 (71.1) 23 (95.8) 9 (42.9) 12 (66.7) 20 (74.1) Female 13 (28.9) 1 (4.2) 12 (57.1) 6 (33.3) 7 (25.9) Age 59.1 (6) 58 (5.2) 60.3 (6.6) 0.2 57.8 (4.6) 59.9 (6.7) 0.3 Weight (kg) 79.9 (18.8) 90.4 (17.4) 67.9(12.16) <0.01 79.7 (18.9) 80.0 (19.2) 1.0 Length (m) 1.8 (0.1) 1.8 (0.1) 1.8 (0.1) 0.3 1.8 (0.1) 1.8 (0.1) 0.8 BMI kg/m 2 18.5-24.9 16 (35.6) 4 (16.7) 12 (57.1) <0.01 4 (22.2) 12 (44.4) 0.07 <18.5 4 (8.9) 0 (0) 4 (19.0) 2 (11.1) 2 (7.4) 25-29.9 18 (40.0) 14 (58.3) 4 (19.0) 11 (61.1) 7 (25.9) ≥30 7 (15.6) 6 (25.0) 1 (4.8) 1 (5.6) 6 (22.2) LSMI cm 2 /m 2 (median, IQR) 44.1 (37.7-50.9) 50.6 (5.2) 36.9 (4.1) <0.01 45.0 (8.6) 43.7 (8.3) 0.6 *Low SMM is defined as an LSMI ≤ 43.2 cm/m2 CISPLATIN DOSE-LIMITING TOXICITY Of the 45 included patients, 26 patients (57.8%) did not complete 3 cycles of cisplatin. All were due to CDLT and consisted of: creatinine increase grade 2 (n=11) and grade 3 (n=2), nausea grade 3 (n=3), hearing impairment grade 2 (n=6), neutropenia grade 3 (n=1), heart failure grade 3 and increased creatinine grade 3 (n=1), creatinine increase grade 2, hypomagnesaemia grade 3 and hyponatremia grade 3 (n=1), hearing impaired grade 2 and neutropenia grade 4 (n=1). In our dataset no correlation was found between CDLTs and SMM (unpaired T-test, p =0.39), as illustrated in figure 1. Figure 1. Correlation between dose limiting toxicities (DLTs) of cisplatin and skeletal muscle mass (un - paired T-test; p=0.39) 14